INMED PHARMACEUTICALS INC. Additional Paid in Capital, Common Stock
INMED PHARMACEUTICALS INC. (INM) had Additional Paid in Capital, Common Stock of $36.89 million as of 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-09-09
- 2026-06-30: Additional Paid in Capital, Common Stock $36.89M.
- 2026-03-31: Additional Paid in Capital, Common Stock $38.14M.
- 2025-12-31: Additional Paid in Capital, Common Stock $38.41M.
- 2025-09-30: Additional Paid in Capital, Common Stock $38.62M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $36.89M S-4/A · filed 2026-09-09 |
| 2026-03-31 | $38.14M S-4 · filed 2026-07-02 |
| 2025-12-31 | $38.41M 10-Q · filed 2026-02-11 |
| 2025-09-30 | $38.62M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $39.32M S-4/A · filed 2026-09-09 |
| 2025-03-31 | $34.89M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $34.84M 10-Q · filed 2025-02-12 |
| 2024-09-30 | $34.82M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $35.37M S-4 · filed 2026-07-02 |
| 2023-09-30 | $35.77M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $35.74M 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |